Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Jean-Louis Steimer"'
Autor:
Mouna Akacha, Christian Bartels, Björn Bornkamp, Frank Bretz, Neva Coello, Thomas Dumortier, Michael Looby, Oliver Sander, Heinz Schmidli, Jean‐Louis Steimer, Camille Vong
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 4, Pp 279-282 (2021)
Externí odkaz:
https://doaj.org/article/3b8ad428c84940ed841522ba4471f1f8
Autor:
Camille Vong, Frank Bretz, Thomas Dumortier, Jean-Louis Steimer, Heinz Schmidli, Oliver Sander, Christian Bartels, Neva Coello, Michael Looby, Björn Bornkamp, Mouna Akacha
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 4, Pp 279-282 (2021)
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 4, Pp 279-282 (2021)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65b2a3a113051d2dd0574116bf28360d
https://pubmed.ncbi.nlm.nih.gov/33951755
https://pubmed.ncbi.nlm.nih.gov/33951755
Publikováno v:
Int. Journal of Clinical Pharmacology and Therapeutics. 44:655-667
Introduction: Ibandronate is a potent, nitrogen-containing bisphosphonate that is licensed as a once-monthly oral preparation and is currently in clinical development as a novel intermittent intravenous (i.v.) injection in osteoporosis. Ibandronate p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::312c665b1dd5e3cd020d7da0a221be3f
https://doi.org/10.5414/cpp44655
https://doi.org/10.5414/cpp44655
Publikováno v:
Journal of Pharmacokinetics and Pharmacodynamics. 32:161-183
Few scientific contributions have made significant impact unless there was a champion who had the vision to see the potential for its use in seemingly disparate areas-and who then drove active implementation. In this paper, we present a historical su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04dec213432cce6772d33321c6b4fb14
https://doi.org/10.1007/s10928-005-0062-y
https://doi.org/10.1007/s10928-005-0062-y
Autor:
R. C. Schimmer, Philippe Jacqmin, Ronald Gieschke, Jean-Louis Steimer, Timothy Goggin, Goonaseelan Pillai
Publikováno v:
British Journal of Clinical Pharmacology. 58:618-631
Aims Ibandronate, a highly potent nitrogen-containing bisphosphonate, is the subject of an ongoing clinical development programme that aims to maximize the potential of simplified, less frequent oral and intravenous (i.v.) administration in osteoporo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95723b9dc585e8425950b40c79215c2e
https://doi.org/10.1111/j.1365-2125.2004.02224.x
https://doi.org/10.1111/j.1365-2125.2004.02224.x
Autor:
Ronald Gieschke, Karen Smith Blesch, Bruno Reigner, Yuko Tsukamoto, Jean-Louis Steimer, Hans Ulrich Burger
Publikováno v:
Investigational New Drugs. 21:195-223
Preclinical studies, along with Phase I, II, and III clinical trials demonstrate the pharmacokinetics, pharmacodynamics, safety and efficacy of a new drug under well controlled circumstances in relatively homogeneous populations. However, these types
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71214a7a1b8b062750df710a166e62c3
https://doi.org/10.1023/a:1023525513696
https://doi.org/10.1023/a:1023525513696
Publikováno v:
British Journal of Clinical Pharmacology. 55:252-263
Aims To assess the relationship between systemic exposure to capecitabine metabolites and parameters of efficacy and safety in patients with advanced or metastatic colorectal cancer from two phase III studies. Methods Concentration–effect analyses
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::54af1a631223ba05eb76afff316296f3
https://doi.org/10.1046/j.1365-2125.2003.01765.x
https://doi.org/10.1046/j.1365-2125.2003.01765.x
Publikováno v:
Journal of Pharmacokinetics and Pharmacodynamics. 29:25-47
Capecitabine has been developed as an orally administered tumor selective fluoropyrimidine for use in the treatment of breast and colorectal cancer. The metabolic pathway for capecitabine includes 5'-deoxy-5-fluorocytidine (5'-DFCR) and 5'-deoxy-5-fl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c15209a66afabfa4c2baf45503ca0f16
https://doi.org/10.1023/a:1015716617967
https://doi.org/10.1023/a:1015716617967
Publikováno v:
Clinical Pharmacology & Therapeutics. 67:610-620
Objective To use pharmacostatistical models to evaluate the overall exposure of patients with Parkinson's disease to levodopa in the presence and absence of tolcapone. Methods Four hundred twelve patients with Parkinson's disease with fluctuating and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19c1809704a64242377ade80f8866973
https://doi.org/10.1067/mcp.2000.106795
https://doi.org/10.1067/mcp.2000.106795
Publikováno v:
British Journal of Clinical Pharmacology. 49:39-48
Aims To use pharmacostatistical models to characterize tolcapone's pharmacokinetics in parkinsonian patients, and to identify any demographic subpopulations which may be at risk of either under- or over-exposure to this catechol-O-methyltransferase (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c69719138c32c850b6003b2b1bf710ce
https://doi.org/10.1046/j.1365-2125.2000.00113.x
https://doi.org/10.1046/j.1365-2125.2000.00113.x